Publications by authors named "Jay Erdman"

Claim this Profile
P
Pediatric Lung Transplant Outcomes Based on Immunosuppressive Regimen at Discharge: Retrospective Cohort Study Using Real-World Evidence From the US Scientific Registry of Transplant Recipients.
Jay Erdman, Josephine Wolfram, David Nimke, Richard Croy, Xuegong Wang

Transplant Proc· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA receptor, and morphine in recreational opioid users.
Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Jay Erdman

J Psychopharmacol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder.
Mototsugu Ito, Mark Walzer, Mary Beth Blauwet, Anna Spence, Nakyo Heo, Jay Erdman

J Psychopharmacol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lung Transplant Outcomes in Adults in the United States: Retrospective Cohort Study Using Real-world Evidence from the SRTR.
Jay Erdman, Josephine Wolfram, David Nimke, Richard Croy, Xuegong Wang

Transplantation· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASP5094, a humanized monoclonal antibody against integrin alpha-9, did not show efficacy in patients with rheumatoid arthritis refractory to methotrexate: results from a phase 2a, randomized, double-blind, placebo-controlled trial.
Tsutomu Takeuchi, Yoshiya Tanaka, Jay Erdman, Yuichiro Kaneko, Masako Saito

Arthritis Res Ther· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, phase 2 study of ASP0113, a DNA-based vaccine, for the prevention of CMV in CMV-seronegative kidney transplant recipients receiving a kidney from a CMV-seropositive donor.
Flavio Vincenti, Klemens Budde, Pierre Merville, Fuad Shihab, V Ram Peddi, Jay Erdman

Am J Transplant· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis